lumify — PDUFA
H1 2027
In addition, Bausch + Lomb is in the process of initiating a Lumify ® next generation clinical study, for which a Phase 3 study met all primary and secondary endpoints and for which the New Drug Application has been submitted and approval is anticipated during the first half of 2027.Source filing